Reevaluating NICE’s Cost-Effectiveness Th...

By João L. Carapinha

December 17, 2024

NICE (National Institute for Health and Clinical Excellence) recently commented on whether their cost-effectiveness thresholds should change, focusing on the intricate relationship between quality-adjusted life years (QALYs) and the incremental co...
Egypt’s Hepatitis C Program: A Model for Africa’s Health Initiatives
Maturity Level 3 in Medicines Regulation in Senegal and Rwanda
Infection Control and Disease Surveillance in Africa
Canada’s Drug Agency Launches Consultation on New Methods Guide for Hea...
Sanofi’s 340B Rebate Model: A Joint Effort to Reform Drug Pricing Pract...
Addressing Physical Inactivity in MENA and Beyond
Smartening Africa’s Drug Supply Chain with IBM AI
Enhancing Primary Health Care Services: Strategies and Insights
Transforming Healthcare: Key Trends in South African Healthtech
Lawsuits Challenge 340B Drug Pricing Program: Eli Lilly and J&J vs. HRSA
Rising Diabetes Prevalence in the Middle East and North Africa
Diabetes Crisis in South Africa: Prevalence, Impact, and Solutions